For which patients with relapsed/refractory follicular lymphoma do you prefer bispecific antibody-based therapy at 2L vs reserving it for later?

Bispecific antibody-based therapy for 2L FL is a very effective treatment option with high rates of overall response, complete response, and what thus far appears to be durable responses. In the EPCORE FL-1 trial, where patients were randomized to epcoritamab + R2 vs R2, it did add more toxicity to ...

I do not reserve therapies for later lines. Most treatments work better earlier than later, and it makes no sense to "save" your best treatments for later.